fingolimod / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 70 Diseases   34 Trials   34 Trials   6123 News 
44 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
fingolimod / Generic mfg.
2014-001012-19: Effects of fingolimod on advanced brain measures and clinical measures in multiple sclerosis De effecten van fingolimod op geavanceerde hersenmaten en klinische maten in multiple sclerose

Ongoing
4
70
Europe
Interferon Beta, Capsule, , Solution for injection in pre-filled syringe, Gilenya, Copaxone
VU University Medical Center, Novartis Pharma
Relapsing-remitting (RR) multiple sclerosis (MS) Relapsing-remitting (RR) multiple sclerose (MS), multiple sclerosis (MS) multiple sclerose (MS), Diseases [C] - Nervous System Diseases [C10]
 
 
2012-000411-91: Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod Untersuchung der natürlichen Killer (NK-) Zellen in Patienten mit Multipler Sklerose unter Fingolimod-Behandlung

Ongoing
4
40
Europe
Gilenya®, Gilenya®, Gilenya®, Gilenya®
Charité - Universitätsmedizin Berlin, Charité - Universitätsmedizin Berlin, Novartis
relapsing-remitting multiple sclerosis
 
 
2013-004626-28: Aivojen mikroglia-solujen aktivaation yhteys MS-tautiin

Ongoing
4
60
Europe
beetainterferoni -1a, Fingolimodi, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada
Turku University Hospital, Novartis Pharma
Multiple sclerosis MS-tauti
 
 
2014-000296-12: Voidaanko aivojen mikroglia-solukon aktiivisuutta vähentää ms-potilaan aivoissa?

Ongoing
4
10
Europe
Fingolimodi, Gilenya, Gilenya
Turku University Hospital, Novartis
Multiple sclerosis MS-tauti
 
 
2017-000559-26: A multicentric, international study in order to compare the effectiveness of fingolimod versus dimethyl-fumarate on patients with Multiple Sclerosis. Studio multicentrico, internazionale volto a confrontare l'efficacia di fingolimod e dimetil-fumarato in pazienti con Sclerosi Multipla

Ongoing
4
1360
Europe
Capsule, hard, Gastro-resistant capsule, hard, GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER DIVISIBILE PER DOSE UNITARIA(PVC/PVDC/ALU) SCATOLA DA 7X1 CAPSULE, TECFIDERA - 240 MG - CAPSULA RIGIDA GASTRORESISTENTE - USO ORALE - BLISTER (PVC/PE/PVDC-PVC ALLUMINIO) - 56 CAPSULE
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA, Patient-Centered Outcomes Research Institute
relapsing-remitting multiple sclerosis sclerosi multipla recidivante-remittente, multiple sclerosis sclerosi multipla, Diseases [C] - Nervous System Diseases [C10]
 
 
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
2013-002433-38: Essai visant à tester la différence d’efficacité du Natalizumab, versus le fingolimod, 2 médicaments pour le traitement de la sclérose en plaques

Not yet recruiting
4
500
Europe
natalizumab, fingolimod, Concentrate for solution for infusion, Capsule, TYSABRI, GILENYA
CHU de Toulouse, FP7 Health Innovation-1
Sclérose en plaques, Sclérose en plaques, Diseases [C] - Nervous System Diseases [C10]
 
 
2012-000674-31: A 3-year, multi-center study to describe the long term changes of optical coherence tomography (OCT) parameters in patients under treatment with Gilenya®

Not yet recruiting
4
100
Europe
Fingolimod, FTY720, Capsule, hard, Gilenya
Novartis Pharma GmbH, Novartis Pharma GmbH
RNFLT in Patients with relapsing remitting Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
2021-003195-13: Importance of monitoring of drugs used in the treatment of multiple sclerosis Význam terapeutického monitorování perorálně podávaných léčiv modifikující průběh choroby (“disease-modifying drugs”) užívaných k léčbě roztroušené sklerózy

Not yet recruiting
4
800
RoW
Aubagio 14MG TBL FLM, Mavenclad 10MG TBL NOB, Tecfidera 240MG CPS ETD, Gilenya 0,5MG CPS DUR, Tablet, Capsule, Aubagio 14MG TBL FLM, Mavenclad 10MG TBL NOB, Tecfidera 240MG CPS ETD, Gilenya 0,5MG CPS DUR
Fakultní nemocnice Ostrava, Fakultní nemocnice Ostrava
multiple sclerosis roztroušená skleróza, multiple sclerosis roztroušená skleróza, Diseases [C] - Nervous System Diseases [C10]
 
 
2022-004331-23: Monitoring of drugs used in the treatment of multiple sclerosis Sledování léčiv užívaných při léčbě roztroušené sklerózy

Not yet recruiting
4
150
RoW
Aubagio 14MG TBL FLM, Gilenya 0,5MG CPS DUR, Tablet, Capsule, hard, Aubagio 14MG TBL FLM, Gilenya 0,5MG CPS DUR
Fakultní nemocnice Ostrava, Fakultní nemocnice Ostrava
multiple sclerosis roztroušená skleróza, multiple sclerosis roztroušená skleróza, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05307731: Fingolimod for Type 2 Diabetes Mellitus

Recruiting
4
40
RoW
Fingolimod, guideline-based treatment for DM
General Hospital of Shenyang Military Region
Diabetes Mellitus, Type 2
03/25
03/25
NTZ2TTY, NCT02769689: Methylprednisolone During the Switch Between Natalizumab and Fingolimod

Recruiting
4
56
Europe
Methylprednisolone, Placebo, natalizumab (NTZ), fingolimob (FTY)
University Hospital, Clermont-Ferrand
Multiple Sclerosis
06/24
07/24
SPRING, NCT04480853: Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Recruiting
4
30
RoW
Fingolimod, FTY720
Novartis Pharmaceuticals
Multiple Sclerosis
01/26
01/26
NCT04667949: Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients

Active, not recruiting
4
98
RoW
Fingolimod 0.5mg, FTY720
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis (RMS)
04/25
04/25
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
2004-000655-41: A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients maintained on a triple immunosuppressive regimen with either MPA or mTOR inhibitor

Ongoing
3
10
Europe
FTY720, FTY720,
Novartis Farmacéutica S.A
prevention of acute rejection in maintenance renal transplant recipients
 
 
PARADIGMS, NCT01892722 / 2011-005677-23: Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Checkmark PARADIGMS
Sep 2017 - Sep 2017: PARADIGMS
Recruiting
3
245
Europe, Canada, US, RoW
Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
Novartis Pharmaceuticals
Multiple Sclerosis
07/17
07/29
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive

Not yet recruiting
3
250
Europe
AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion
CHU de Rennes, CHU de Rennes
Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-004431-24: A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108 Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple Sclerosis Estudio para evaluar la eficacia, seguridad, farmacocinética y farmacodinamia de ponesimod frente a fingolimod durante 108 semanas de tratamiento en pacientes pediátricos, de 10 a <18 años, con esclerosis múltiple remitente recurrente.

Ongoing
3
212
Europe, RoW
Ponesimod, Fingolimod, JNJ-67896153/ACT-128800, Film-coated tablet, Capsule, Gilenya hard capsules
Janssen-Cilag International NV, Janssen Research & Development, LLC
Relapsing-remitting Multiple Sclerosis Esclerosis múltiple remitente recurrente., Chronic inflammatory disease attacking the CNS Enfermedad inflamatoria crónica que ataca al SNC., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT06408259: Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Not yet recruiting
3
194
US, RoW
Ozanimod, Fingolimod, Placebo
Celgene
Multiple Sclerosis, Relapsing-Remitting
04/31
07/36
ARTIOS, NCT04353492 / 2019-001341-40: An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

Active, not recruiting
3
564
Europe, Canada, US, RoW
Ofatumumab, OMB157
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
04/25
04/25
Operetta 2, NCT05123703 / 2020-004128-41: A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis

Recruiting
3
171
Europe, Canada, US, RoW
Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo
Hoffmann-La Roche, PPD DEVELOPMENT, LP
Relapsing-Remitting Multiple Sclerosis
07/25
09/29
NEOS, NCT04926818 / 2020-002700-39: Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Recruiting
3
120
Europe, Canada, US, RoW
Fingolimod, FTY720, Ofatumumab, OMB157, Siponimod, BAF312, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Multiple Sclerosis (MS)
03/27
12/31
MIST, NCT03133403 / 2012-004165-41: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

Recruiting
2/3
5
Europe
Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT)
Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
12/21
12/21
2004-000664-27: A 34 week, open label, single cohort, exploratory study to evaluate the effect of FTY720 on chronic Hepatitis C in patients who are non-responsive to, or intolerant of Interferon-based antiviral therapy

Ongoing
2
10
Europe
FTY720, FTY720,
Novartis Farmaceutica S.A.
Chronic Hepatitis C
 
 
NCT04629872: Fingolimod in Endovascular Treatment of Ischemic Stroke

Recruiting
2
30
RoW
Fingolimod
Ning Wang, MD., PhD.
Stroke Inflammation
12/22
12/23
NCT06424067: Phase 2 Study of Fingolimod in Lung Cancers

Not yet recruiting
2
38
NA
Fingolimod 0.5 milligram (mg) [Gilenya]
Medical University of South Carolina
Non Small Cell Lung Cancer, Small-cell Lung Cancer
11/26
11/27
NCT05285878: Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

Enrolling by invitation
2
20
US
Fingolimod, GILENYA®, FTY720, Placebo, methylcellulose
The Methodist Hospital Research Institute
Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection, Kidney Transplant Failure, Kidney Failure, Chronic, Graft Rejection
01/25
09/25
FAMTAIS II, NCT04675762: Combinating Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic Stroke

Recruiting
2
118
RoW
Fingolimod, Placebo
Second Affiliated Hospital, School of Medicine, Zhejiang University, Shaoxing People's Hospital, Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, The Second Affiliated Hospital of Jiaxing University, Jinhua Center Hospital, Taizhou Hospital
Stroke, Inflammation
12/25
03/26
FMIICH, NCT06087965: Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage

Not yet recruiting
1/2
40
NA
Fingolimod
Tang-Du Hospital
Intracerebral Hemorrhage
06/25
12/25
ACTRN12618002016213: A study to evaluate the safety and tolerability of an investigational transdermal patch containing Fingolimod in healthy volunteers.

Not yet recruiting
1
12
 
INC Research Australia Pty Ltd, Corium International, Inc.
Multiple sclerosis
 
 
ACTRN12618002016213p: A study to evaluate the safety and tolerability of an investigational transdermal patch containing Fingolimod in healthy volunteers.

Not yet recruiting
1
12
 
INC Research Australia Pty Ltd, Corium International, Inc.
Multiple sclerosis
 
 
NCT03941743: Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer

Completed
1
2
US
Fingolimod, Fingolimod Hydrochloride, FTY-720, FTY720, Gilenya, Questionnaire Administration
Mayo Clinic, National Cancer Institute (NCI)
Breast Carcinoma
06/20
11/21
NCT03943498: Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy

Completed
1
2
US
Fingolimod, Fingolimod Hydrochloride, FTY-720, FTY720, Gilenya, Questionnaire Administration
Mayo Clinic, National Cancer Institute (NCI)
Chemotherapy-Induced Peripheral Neuropathy, Numbness, Pain, Tingling
12/20
12/20
FITCH, NCT04088630: Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage

Completed
1
28
US
Fingolimod 0.5 mg, Gilenya, Placebo, Standard of care
Wake Forest University Health Sciences, National Center for Advancing Translational Sciences (NCATS)
Intracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic, Intracerebral Hemorrhage, Hypertensive, Intracerebral Hemorrhage Intraparenchymal
06/23
06/24
REPAIR FAST, NCT04718064: Revascularization Pretreated With Fingolimod in Acute Stroke

Not yet recruiting
N/A
20
NA
Fingolimod, placebo
The Affiliated Hospital of Xuzhou Medical University
Stroke
10/21
01/22
CPE, NCT05762003: Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

Completed
N/A
17478
RoW
interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
IMPULS Endowment Fund
Multiple Sclerosis
12/21
12/21
COMBAT-MS, NCT03193866 / 2016-003587-39: COMparison Between All immunoTherapies for Multiple Sclerosis.

Active, not recruiting
N/A
3526
Europe
Rituximab, Natalizumab, Fingolimod, Alemtuzumab, Interferon-beta, Glatiramer acetate, Dimethyl Fumarate
Karolinska Institutet, Patient-Centered Outcomes Research Institute, Kaiser Foundation Research Institute
Relapsing-remitting Multiple Sclerosis
12/22
12/22
NCT05423769: Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt

Completed
N/A
30
RoW
Fingolimod, Sphingomod®, Hikma
Hikma Pharmaceuticals LLC
Relapsing-Remitting Multiple Sclerosis
11/23
11/23
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Recruiting
N/A
900
US
Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy, Tysabri, Lemtrada, Ocrevus, Rituxan, Mavenclad, Kesimpta, Briumvi, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/25
08/25
STATURE, NCT04676204: Relationship Between Oral DMT Burden and Adherence in MS

Enrolling by invitation
N/A
323
RoW
Cladribine, Mavenclad, Dimethyl fumarate, Tecfidera, Fingolimod, Gilenya, Teriflunomide, Aubagio, Ozanimod, Zeposia, Diroximel fumarate, Vumerity
Monash University
Multiple Sclerosis, Adherence, Medication
11/25
07/26
NCT01285479: The Gilenya Pregnancy Registry

Recruiting
N/A
500
Europe, Canada, US, RoW
Fingolimod
Novartis Pharmaceuticals
Multiple Sclerosis
01/31
01/31
NCT05688436: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
N/A
1178
US
Diroximel Fumarate, VUMERITY, BIIB098, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Tysabri, BG00002, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
Biogen
Multiple Sclerosis
01/31
01/31
NCT05516303: Pharmacogenetics of Liver Toxicity in Patients With Multiple Sclerosis Treated With Fingolimod

Recruiting
N/A
65
Europe
Genetic polymorphism, Measurement of fingolimod and fingolimod-phosphate concentrations
University Hospital, Caen
Multiple Sclerosis
10/22
10/22

Download Options